

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>WEST MICHAEL D</u> (Last) (First) (Middle) <u>1010 ATLANTIC AVENUE</u> <u>SUITE 102</u> (Street) <u>ALAMEDA CA 94501</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIOTIME INC [BTX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Co-Chief Executive Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>04/07/2016</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares, no par value								875,987 ⁽¹⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Option to Purchase Common Shares	\$3.16	04/07/2016		A		175,000		(2)	04/06/2026	Common Shares	175,000	\$0.00	175,000	D	
Restricted Stock Units	(3)	04/07/2016		A		25,000		(4)	(4)	Common Shares	25,000	\$0.00	25,000	D	
Option to Purchase Common Shares	\$3.51							(5)	07/09/2025	Common Shares	200,000		200,000	D	
Option to Purchase Common Shares	\$3.51							(6)	03/19/2021	Common Shares	200,000		200,000	D	
Option to Purchase Common Shares	\$4.22							(7)	02/19/2020	Common Shares	200,000		200,000	D	

Explanation of Responses:

- Does not include shares that may be acquired upon the exercise of certain stock options.
- One quarter of the options shall vest upon the completion of 12 months of continuous employment from the date of grant and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.
- Grant of restricted stock units under the BioTime 2012 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one Common Share.
- One quarter of the restricted stock units shall vest upon the completion of 12 months of continuous employment from the date of grant and the balance shall vest in twelve equal quarterly installments upon completion of each quarter of continuous employment.
- One quarter of the options vested on March 2, 2016 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.
- 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after March 20, 2014.
- 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after January 1, 2013.

Remarks:

/s/ Michael D. West 04/11/2016
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.